NEXEL Co., Ltd. spun off from Korea University in 2012 with its proprietary stem cell technology and by the end of 2017 has introducedHEPATOSIGHT-S and CARDIOSIGHT-S to the market (https://www.nexel.co.kr/private-office). These fully functional human cell products can currently be used for a variety of research, including drug screening and toxicity tests. 

During our research with the stem cell, we were lucky enough to stumble upon a molecule with a significant anti-fibrotic effect. Nexel has carried out various studies to optimize its stability, manufacturability, and efficacy by modifying its structure in collaboration with respected CROs in South Korea. 

The new drug candidate was named NP-011 (https://www.nexel.co.kr/open-space) and has 4-folds higher anti-fibrotic effect compared to its parent molecule. The primary indication for NP-011 is NASH and Liver Fibrosis, and use in other fibrotic diseases are currently being evaluated. NEXEL's goal for NP-011 is to find a partner with experience and expertise for co-development and file for IND by the end of 2019 with K-FDA. 

If you have any questions regarding either of NEXEL's human cells or protein therapy, please feel free to contact at support@nexel.co.kr 

Thank you.

NEXEL

Org chart

Teams

Offices